GOSS

$0.17-$0.01 (-4.11%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$86.8M

489M shares

52-week range

$0.11 – $3.87

2% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-8.08

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$35M	-17.9%	$-0.37	$-0.52–$-0.22	—	5
2027	$53M	+53.8%	$-0.09	$-0.26–$0.01	—	5
2028	$132M	+148.5%	$0.06	$-0.48–$0.86	3.0×	5
2029	$242M	+82.4%	$0.20	$0.04–$0.46	0.9×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-0.12	$-0.20	-62.0%
2026-05-18	$-0.17	$-0.20	-17.6%
2026-03-17	$-0.20	$-0.21	-5.0%
2025-11-05	$-0.19	$-0.21	-10.5%
2025-08-05	$-0.18	$-0.17	+5.6%
2025-05-15	$-0.18	$-0.16	+11.1%
2025-03-13	$-0.17	$-0.15	+11.8%
2024-11-07	$-0.18

DCF fair valuemodel estimate

Intrinsic value

$1.32

Price

$0.17

Implied upside

+673%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GOSSGossamer Bio, Inc.	$0.17	-4.11%	$83M	—
CRVSCorvus Pharmaceuticals, Inc.	$15.14	+0.60%	$1.3B	—
FDMT4D Molecular Therapeutics, Inc.	$11.65	-1.85%	$609M	—
KALVKalVista Pharmaceuticals, Inc.	$27.00	+0.00%	$1.4B	—
LXRXLexicon Pharmaceuticals, Inc.	$2.34

Gossamer Bio, Inc. Common Stock

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

www.gossamerbio.com

Employees: 162
IPO / List date: Feb 8, 2019
HQ: SAN DIEGO, CA

Held by traders on TradeandTell

No one on the platform currently holds GOSS.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	1,217,868	$400.1K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded GOSS yet.

$GOSS chatter on StockTwits

0xtechnerd@0xtechnerdBullish6h
$GOSS
View on StockTwits ↗
kodeman@kodemanBullish7h
$GOSS anyone know how the call is going?
View on StockTwits ↗
Aura@ExploringTradesBullish7h
Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $SLNH $GOSS Earning!
View on StockTwits ↗
Mike Sevens@AtariLynxBullish9h
$GOSS looking good!
View on StockTwits ↗
Mike Sevens@AtariLynx9h
$GOSS https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-second-quarter-2026-financial-results-and
View on StockTwits ↗
Bullero@TilTUPBullish9h
$GOSS great earning results :
View on StockTwits ↗
prat1703@prat1703Bearish9h
$GOSS : Verdict is out - close your positions or wait till dilution which will take away 30-40% of whatever's left! 1. The company has told its auditors it may not survive the year. "Going concern" doubt is now in the quarterly filing, not just the annual one. They say cash lasts into Q1 2027. 2. Here's the part nobody's talking about: their loan agreement requires them to keep at least $40M in the bank, checked every single month. They have $57M and burn about $13-14M a month. That's roughly two months of breathing room. 3. So the fundraise isn't a Q1 2027 problem. It's a September-October problem.The lenders basically told them how much to raise. The $40M requirement drops to $20M only after they raise $100M+, and disappears entirely after $150M+. That's the size of the raise, written into the loan.
View on StockTwits ↗
jorge .miguel@focafoca999h
$GOSS disclosed its June 30, 2026 quarter results via a press release attached to the 8-K.
View on StockTwits ↗
CoachHendo@CoachHendo9h
$GOSS not too shabby. See how it plays out.
View on StockTwits ↗
Mike Sevens@AtariLynx10h
$GOSS Can someone explain what happen in post market and why don’t happen during a regular market day?
View on StockTwits ↗
James Di Piazza@Jdp0765210h
$GOSS doesn’t look good.
View on StockTwits ↗
Alex ro@AlexRo77710h
$GOSS since last earnings was the last nail in the coffin
View on StockTwits ↗
Alex ro@AlexRo77710h
$GOSS painful to watch
View on StockTwits ↗
Mike Sevens@AtariLynxBullish11h
$GOSS there is still time to say : “it will go up tomorrow”. Come on!
View on StockTwits ↗
Bullero@TilTUP11h
$GOSS
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.